Miguel Angel Diaz

List of Publications by Year
in descending order

199 papers	4,734 citations	117625 34 h-index	168389 53 g-index
211 all docs	211 docs citations	211 times ranked	5802 citing authors

#	Article	IF	Citations
1	HEV infection in stem cell transplant recipientsâ€"retrospective study of EBMT Infectious Diseases Working Party. Bone Marrow Transplantation, 2022, 57, 167-175.	2.4	6
2	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
3	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplantation and Cellular Therapy, 2022, 28, 603.e1-603.e7.	1.2	4
4	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy, 2022, 28, 712.e1-712.e8.	1.2	3
5	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
6	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
7	Plerixaforâ€based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp>⁺ collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	1.3	3
8	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12
9	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
10	Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). European Journal of Haematology, 2021, 106, 842-850.	2.2	2
11	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1900-1907.	2.4	18
12	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
13	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
14	â€œExâ€vivoâ€•Tâ€cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges. European Journal of Haematology, 2021, 107, 38-47.	2.2	5
15	Graft failure after â€œex-vivoâ€•T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis. Leukemia and Lymphoma, 2021, 62, 1-8.	1.3	3
16	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
17	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
18	Comparison of clinical outcomes between unrelated single umbilical cord blood and â€œex-vivoâ€•T-cell depleted haploidentical transplantation in children with hematological malignancies. World Journal of Pediatrics, 2021, 17, 609-618.	1.8	2

#	Article	IF	Citations
19	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	1.4	4
20	Haploidentical transplantation in highâ€risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). American Journal of Hematology, 2020, 95, 28-37.	4.1	34
21	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
22	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€"Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	5.9	40
23	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
24	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
25	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
26	Impact of autologous blood transfusion after bone marrow harvest on unrelated donorâ€™s health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
27	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
28	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
29	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 1747-1756.	2.0	7
30	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4
31	COVIDâ€19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH). Pediatric Blood and Cancer, 2020, 67, e28514.	1.5	57
32	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	4.1	30
33	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
34	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances, 2020, 4, 706-716.	5.2	11
35	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. Blood, 2020, 136, 45-47.	1.4	0
36	Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. American Journal of Hematology, 2019, 94, 319-326.	4.1	59

#	Article	IF	Citations
37	Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study. Biology of Blood and Marrow Transplantation, 2019, 25, 100-106.	2.0	11
38	Allogeneic stem cell transplantation for acquired pure red cell aplasia. American Journal of Hematology, 2019, 94, E294-E296.	4.1	9
39	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
40	Hashimoto encephalopathy as manifestation of central nervous system chronic graftâ€versusâ€host disease after hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2019, 66, e28008.	1.5	2
41	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
42	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
43	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplantation, 2019, 54, 1354-1360.	2.4	19
44	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
45	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
46	CD45 RA Depletion As an Allogeneic Hematopoietic Transplantation Platform in Children from HLA-Identical Donors. Biology of Blood and Marrow Transplantation, 2019, 25, S205-S206.	2.0	0
47	Ruxolitinib Treatment for Steroid Refractory ACUTE and Chronic GRAFT Versus Host Disease in Children: Clinical and Immunological Results. Biology of Blood and Marrow Transplantation, 2019, 25, S257-S258.	2.0	1
48	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
49	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
50	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Advances, 2019, 3, 2525-2536.	5.2	13
51	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
52	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using Î±Î²+ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. Frontiers in Immunology, 2019, 10, 2504.	4.8	13
53	Ocular toxocariasis in a pediatric patient undergoing a bone marrow transplantation. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 618.	0.3	0
54	Toxoplasmosis and secondary Guillainâ€BarrÃ© associated with ruxolitinib as graftâ€versusâ€host disease treatment. Pediatric Blood and Cancer, 2019, 66, e27446.	1.5	6

#	Article	IF	Citations
55	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
56	Ocular toxocariasis in a pediatric patient undergoing a bone marrow transplantation. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 617-618.	0.5	1
57	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 301-306.	2.0	27
58	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo EspaÃ±ol De Trasplante de Medula Osea en NiÃ±os (GETMON) and the Grupo EspaÃ±ol de Trasplante Hematopoyetico (GETH). Transfusion Medicine Reviews, 2018, 32, 179-185.	2.0	30
59	Reduced-intensity conditioning haematopoietic stem cell transplantation in genetic diseases: Experience of the Spanish Working Group for Bone Marrow Transplantation in Children. Anales De PediatrÃa (English Edition), 2018, 88, 196-203.	0.2	0
60	Neurocysticercosis: An unusual seizure etiology in a hematopoietic stem cell transplanted patient. Pediatric Hematology and Oncology, 2018, 35, 20-22.	0.8	4
61	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	2.9	233
62	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018, 24, 799-805.	2.0	22
63	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
64	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1629-1642.	2.0	44
65	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biology of Blood and Marrow Transplantation, 2018, 24, 478-485.	2.0	31
66	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
67	Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells. Clinical and Translational Oncology, 2018, 20, 584-590.	2.4	5
68	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
69	Herpes 6 Encephalitis: Clinical and Immunological Characteristics in Pediatric Patients with Leukemia Undergoing Depleted Haploidentical Hematopoietic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S432-S433.	2.0	1
70	Donor KIR Genotype Impacts on Clinical Outcome after T Cellâ€“Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. Biology of Blood and Marrow Transplantation, 2018, 24, 2493-2500.	2.0	20
71	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Advances, 2018, 2, 49-60.	5.2	45
72	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. British Journal of Haematology, 2018, 183, 110-118.	2.5	53

#	Article	IF	Citations
73	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
74	Impact of preâ€transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer, 2017, 123, 1828-1838.	4.1	73
75	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. Leukemia Research, 2017, 57, 60-64.	0.8	33
76	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1523-1530.	2.0	13
77	Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era. Biology of Blood and Marrow Transplantation, 2017, 23, S94-S95.	2.0	0
78	Influence of a Moderate-Intensity Exercise Program on Early NK Cell Immune Recovery in Pediatric Patients After Reduced-Intensity Hematopoietic Stem Cell Transplantation. Integrative Cancer Therapies, 2017, 16, 464-472.	2.0	23
79	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	3.5	43
80	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplantation, 2017, 52, 1616-1622.	2.4	44
81	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
82	Lipomatous hypertrophy of the interatrial septum, an unusual tachycardia etiology in a hematopoietic stem cell transplanted patient. Pediatric Hematology and Oncology, 2017, 34, 144-145.	0.8	1
83	Allogeneic Transplantation for Relapsed WaldenstrÃ¶m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 60-66.	2.0	17
84	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
85	Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapsed Acute Leukemia in Children - an EBMT PDWP Retrospective Study. Blood, 2017, 130, 912-912.	1.4	0
86	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplantation, 2016, 51, 1211-1216.	2.4	29
87	The therapeutic potential of natural killer cells to target medulloblastoma. Expert Review of Anticancer Therapy, 2016, 16, 573-576.	2.4	14
88	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biology of Blood and Marrow Transplantation, 2016, 22, 520-527.	2.0	14
89	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplantation, 2016, 51, 1482-1489.	2.4	28
90	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. Clinical Laboratory, 2016, 62, 1243-1248.	0.5	1

#	Article	IF	Citations
91	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
92	Intensive Care Unit Admissions Among Children After Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2015, 37, 529-535.	0.6	18
93	Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cellâ€“mediated cytotoxicity against neuroblastoma inÂvitro and inÂvivo. Cytotherapy, 2015, 17, 601-612.	0.7	57
94	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1273-1277.	2.0	24
95	ATG in paediatric haemopoietic stem cell transplantation. Lancet Haematology,the, 2015, 2, e178-e179.	4.6	2
96	A phase I/II trial of interleukin-15â€“stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy, 2015, 17, 1594-1603.	0.7	69
97	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
98	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia and Lymphoma, 2015, 56, 656-662.	1.3	32
99	Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database. Bone Marrow Transplantation, 2014, 49, 767-772.	2.4	4
100	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood, 2014, 123, 1615-1620.	1.4	56
101	Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome. Biology of Blood and Marrow Transplantation, 2013, 19, 893-897.	2.0	39
102	Defining â€œpoor mobilizerâ€•in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy, 2013, 15, 132-137.	0.7	14
103	Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). Transfusion and Apheresis Science, 2013, 49, 234-237.	1.0	2
104	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virusâ€“Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2013, 57, 794-802.	5.8	196
105	In vitro Natural Killer Cell Immunotherapy for Medulloblastoma. Frontiers in Oncology, 2013, 3, 94.	2.8	35
106	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. British Journal of Cancer, 2013, 109, 2523-2532.	6.4	22
107	Very Late Isolated CNS Relapse of Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 2013, 35, e57-e59.	0.6	3
108	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplantation, 2012, 47, 1419-1427.	2.4	37

#	Article	IF	Citations
109	Once-daily Intravenous Busulfan for 47 Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2012, 34, 180-183.	0.6	8
110	Varicella zoster central nervous system vasculitis after allogeneic hematopoietic stem cell transplant successfully treated with cyclophosphamide. Transplant Infectious Disease, 2012, 14, E107-10.	1.7	2
111	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Experimental Hematology, 2012, 40, 882-891.e1.	0.4	43
112	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood, 2012, 119, 2935-2942.	1.4	82
113	Unrelated cord blood transplantation in adolescent and young adults with hematologic malignancies. Leukemia Research, 2012, 36, 123-124.	0.8	2
114	High-Dose Busulfan and Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Neuroblastoma Patients. Pediatric Hematology and Oncology, 2011, 28, 115-123.	0.8	13
115	High-dose Busulfan and Cyclophosphamide as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Childhood Non-Hodgkin Lymphoma Patients. Journal of Pediatric Hematology/Oncology, 2011, 33, e89-e91.	0.6	16
116	Higher Doses of CD34+ PBPC are Associated With a Rapid Acquisition of Full Donor Chimerism and Lower Risk of Relapse After Allogeneic Transplantation in Pediatric Patients With Hematological Malignancies. Journal of Pediatric Hematology/Oncology, 2011, 33, 185-189.	0.6	5
117	Pulmonary Glial Heterotopia in a Child Diagnosed With Fanconi Anemia and Epilepsy. Journal of Pediatric Hematology/Oncology, 2011, 33, 462-464.	0.6	3
118	Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. Bone Marrow Transplantation, 2011, 46, 119-124.	2.4	44
119	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. European Journal of Haematology, 2011, 87, 46-53.	2.2	29
120	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	1.2	42
121	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology, 2010, 32, e85-e90.	0.6	34
122	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. Journal of Pediatric Hematology/Oncology, 2010, 32, 589-593.	0.6	24
123	Nuclear factor-Â B inducing kinase is required for graft-versus-host disease. Haematologica, 2010, 95, 2111-2118.	3.5	7
124	HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2010, 27, 272-282.	0.8	14
125	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2009, 26, 165-174.	0.8	12
126	Intrathecal liposomal cytarabine in children under 4Âyears with malignant brain tumors. Journal of Neuro-Oncology, 2009, 95, 65-69.	2.9	22

#	Article	IF	Citations
127	KIRâ€“HLA receptorâ€ligand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64
128	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. British Journal of Haematology, 2009, 144, 909-916.	2.5	31
129	Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. Journal of Pediatric Hematology/Oncology, 2009, 31, 642-646.	0.6	54
130	Dyspnea as the first manifestation of primary pancreatic lymphoma. Pediatric Blood and Cancer, 2008, 50, 434-434.	1.5	4
131	Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplantation, 2008, 41, 627-633.	2.4	30
132	Aspergillus â€œfungus ballâ€•of the bladder after hematopoietic transplantation in a pediatric patient: Successful treatment with intravesical voriconazole and surgery. Pediatric Transplantation, 2008, 12, 242-245.	1.0	12
133	Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transplant Infectious Disease, 2008, 10, 193-196.	1.7	19
134	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€matched allogeneic stem cell transplantation in childhood leukaemia patients. British Journal of Haematology, 2008, 140, 340-343.	2.5	10
135	ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSIONâ€”Similar Outcomes After Matched Related and Unrelated Donor Transplant: A Study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). Pediatric Hematology and Oncology, 2008, 25, 245-259.	0.8	11
136	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica, 2008, 93, 1278-1280.	3.5	26
137	Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica, 2008, 93, 735-740.	3.5	62
138	Mesenchymal Stem Cells are of Recipient Origin in Pediatric Transplantations Using Umbilical Cord Blood, Peripheral Blood, or Bone Marrow. Journal of Pediatric Hematology/Oncology, 2007, 29, 388-392.	0.6	17
139	PBSC collection in extremely low weight infants: a single-center experience. Cytotherapy, 2007, 9, 356-361.	0.7	11
140	Extramedullary acute lymphoblastic leukaemia in childhood. European Journal of Haematology, 2007, 79, 182-182.	2.2	0
141	Risk Score for Pediatric Intensive Care Unit Admission in Children Undergoing Hematopoietic Stem Cell Transplantation and Analysis of Predictive Factors for Survival. Journal of Pediatric Hematology/Oncology, 2005, 27, 526-531.	0.6	31
142	Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplantation, 2005, 35, S17-S21.	2.4	11
143	Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983â€“1998. Bone Marrow Transplantation, 2005, 35, 895-901.	2.4	13
144	Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplantation, 2005, 36, 781-785.	2.4	23

#	Article	IF	Citations
145	Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia, 2005, 19, 504-506.	7.2	24
146	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2005, 71, 33-38.	2.9	80
147	Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplantation, 2004, 33, 675-690.	2.4	71
148	Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. Bone Marrow Transplantation, 2004, 34, 433-438.	2.4	10
149	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplantation, 2004, 34, 1051-1055.	2.4	20
150	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation, 2004, 34, 1077-1081.	2.4	14
151	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. Journal of Neuro-Oncology, 2004, 67, 101-106.	2.9	30
152	Risks and methods for peripheral blood progenitor cell collection in small children. Transfusion and Apheresis Science, 2004, 31, 221-231.	1.0	14
153	Fatal Hepatic Failure Secondary to Acute Herpes Simplex Virus Infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 686-688.	0.6	21
154	Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2004, 26, 492-496.	0.6	15
155	Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2004, 26, 117-119.	0.6	5
156	Chemotherapy-Related Secondary Acute Myeloid Leukemia in Patients Diagnosed With Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 454-456.	0.6	12
157	Enfermedad pulmonar obstructiva tras trasplante alogÃ©nico de progenitores hematopoyÃ©ticos en niÃ±os. Anales De PediatrÃa, 2004, 61, 124-130.	0.2	1
158	Heparin based anticoagulation during peripheral blood stem cell collection may increase the CD34+ cell yield. Haematologica, 2004, 89, 249-51.	3.5	14
159	Trasplante autÃ³logo con progenitores hematopoyÃ©ticos de sangre perifÃ©rica en niÃ±os con tumores del sistema nervioso central de alto riesgo. Anales De PediatrÃa, 2004, 61, 8-15.	0.2	1
160	Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Annals of Hematology, 2003, 82, 649-653.	1.8	32
161	Transplantation of marrow cells from children with standard risk-acute lymphoblastic leukemia at the end of therapy into NOD/SCID mice for detecting residual leukemic cells with in vivo growth potential. Leukemia Research, 2003, 27, 1153-1157.	0.8	3
162	Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplantation, 2003, 31, 263-267.	2.4	24

#	Article	IF	Citations
163	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica, 2003, 88, 919-22.	3.5	25
164	TopotecÃ¡n en el tratamiento de niÃ±os con tumores sÃ³lidos refractarios o recidivantes. Anales De PediatrÃa, 2003, 59, 143-148.	0.2	0
165	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 705-709.	1.8	16
166	Peripheral Blood Progenitor Cell Collection in Low-Weight Children. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 633-642.	1.8	13
167	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion, 2002, 42, 4-9.	1.6	87
168	Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. Leukemia Research, 2002, 26, 817-820.	0.8	10
169	Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia. Bone Marrow Transplantation, 2002, 30, 9-13.	2.4	13
170	Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplantation, 2002, 30, 355-358.	2.4	27
171	Granulocyte colony-stimulating factor alone at 12 Î¼g/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplantation, 2002, 30, 417-420.	2.4	30
172	Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. Haematologica, 2002, 87, 292-8.	3.5	41
173	"Pseudotumor cerebri" following allogeneic bone marrow transplantation (BMT). Annals of Hematology, 2001, 80, 236-237.	1.8	18
174	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. British Journal of Haematology, 2001, 114, 544-550.	2.5	23
175	Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion, 2001, 41, 201-205.	1.6	50
176	Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. Bone Marrow Transplantation, 2001, 28, 89-92.	2.4	26
177	Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study. Bone Marrow Transplantation, 2001, 28, 537-543.	2.4	11
178	Ki-1+ANAPLASTIC LARGE CELL LYMPHOMA IN A CHILD WITH UNPREDICTABLE CLINICAL COURSE. Pediatric Hematology and Oncology, 2001, 18, 143-146.	0.8	2
179	Long-Term Hematopoietic Engraftment after Autologous Peripheral Blood Progenitor Cell Transplantation in Pediatric Patients: Effect of the CD34+ Cell Dose. Vox Sanguinis, 2000, 79, 145-150.	1.5	18
180	Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. Bone Marrow Transplantation, 2000, 26, 1291-1298.	2.4	26

#	Article	IF	Citations
181	Autologous stem cell transplantation for advanced Hodgkin's disease in children. Bone Marrow Transplantation, 2000, 25, 31-34.	2.4	28
182	High Survival Rate in Infant Acute Leukemia Treated With Early High-Dose Chemotherapy and Stem-Cell Support. Journal of Clinical Oncology, 2000, 18, 3256-3261.	1.6	34
183	SHORT-TERM FOLLOW-UP OF THE NUTRITIONAL STATUS OF CHILDREN UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. Pediatric Hematology and Oncology, 2000, 17, 559-566.	0.8	10
184	Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors. Bone Marrow Transplantation, 1999, 23, 631-632.	2.4	9
185	An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous peripheral blood stem cell (PBSC) transplantation in a child. Bone Marrow Transplantation, 1999, 23, 735-736.	2.4	1
186	G-CSF-mobilized PBSCT in children with AML in first complete remission. Bone Marrow Transplantation, 1999, 23, 975-976.	2.4	1
187	Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplantation, 1999, 24, 723-728.	2.4	49
188	High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplantation, 1999, 24, 1157-1159.	2.4	46
189	SUCCESSFUL UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION IN A CHILD WITH OMENN'S SYNDROME. Pediatric Hematology and Oncology, 1999, 16, 361-366.	0.8	13
190	Megatherapy in children with high-risk Ewingâ€™s sarcoma in first complete remission. Bone Marrow Transplantation, 1998, 21, 795-799.	2.4	29
191	Progenitor cell subsets and engraftment kinetics in children undergoing autologous peripheral blood stem cell transplantation. British Journal of Haematology, 1998, 101, 104-110.	2.5	28
192	CNS Sequelae in Langerhans Cell Histiocytosis: Progressive Spinocerebellar Degeneration as a Late Manifestation of the Disease. Pediatric Hematology and Oncology, 1997, 14, 577-584.	0.8	12
193	Non-tunneled catheters for the collection and transplantation of peripheral blood stem cells in children. Bone Marrow Transplantation, 1997, 20, 53-56.	2.4	21
194	Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplantation, 1997, 20, 211-217.	2.4	121
195	Clinical relevance of T-cell receptor delta gene rearrangements in childhood B-precursor cell acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 99, 308-313.	2.5	5
196	COLLECTION AND TRANSPLANTATION OF PERIPHERAL BLOOD PROGENITOR CELLS MOBILIzED BY Gâ€CSF ALONE IN CHILDREN WITH MALIGNANCIES. British Journal of Haematology, 1996, 94, 148-154.	2.5	47
197	A Unique Dysembryonic Neoplasm of the Adrenal Gland Composed of Nephrogenic Rests in a Child. American Journal of Surgical Pathology, 1996, 20, 118-124.	3.7	9
198	Complicated Pulmonary Aspergillosis with Pneumothorax and Pneumopericardium in a Child with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 1995, 12, 195-199.	0.8	14

#	Article	IF	Citations
199	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRÎ±Î²+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	2.8	1